DoD Prostate Cancer, Idea Development Award | W81XWH 20 PCRP IDA

Opportunity Information: Apply for W81XWH 20 PCRP IDA

The DoD Prostate Cancer Research Program (PCRP) Idea Development Award (FY20; Funding Opportunity Number W81XWH-20-PCRP-IDA) is designed to fund fresh, high-risk, high-reward concepts in prostate cancer research that could meaningfully move the field forward. The central purpose is to support research ideas that are genuinely innovative rather than incremental, with a clear line of sight to making an important contribution to the PCRP mission and to solving defined program priorities. While the opportunity is open to a wide range of applicant organizations (unrestricted eligibility, subject to any notice-specific requirements), the project itself is expected to be tightly aligned with the program’s expectations around innovation, impact, and scientific rigor.

A defining feature of this award is its emphasis on innovation. Competitive applications are expected to propose approaches that introduce a new paradigm, challenge existing assumptions, reframe long-standing problems, or bring in unusually creative strategies such as leveraging unique study populations or applying methods from other disciplines. The solicitation makes it clear that straightforward, incremental extensions of already published work are not what this mechanism is meant to support. Multidisciplinary projects are explicitly encouraged, and proposals that use data science approaches (for example, advanced bioinformatics, computational modeling, or integrative analyses across large datasets) are viewed as particularly responsive to the intent of the award.

Impact is treated as a co-equal pillar alongside innovation. Applicants must directly address at least one of the FY20 PCRP Overarching Challenges and clearly explain how the proposed work will provide a solution or a meaningful step toward a solution. Reviewers are looking for a convincing description of both near-term and long-term payoffs: what success would produce during the award period (tools, datasets, mechanistic insights, biomarkers, validated targets, or clinically relevant findings) and how that success could translate into significant advances in prostate cancer research and/or patient care over time. In other words, novelty alone is not enough; the application needs a strong argument for why the idea matters and how it could change what researchers or clinicians can do.

Because the mechanism is meant to catalyze new ideas, preliminary data are encouraged but not required. If applicants include unpublished preliminary results, those data are expected to come from the PI’s lab or from members of the research team, reinforcing the expectation that the team has direct familiarity with the approach. Even without preliminary data, the application must rest on solid scientific logic grounded in critical analysis of the literature and a coherent rationale for why the hypothesis and methods are credible. The announcement also signals a strong preference for study designs that maximize rigor and translatability, including practical steps like authenticating cell lines, applying appropriate statistical rigor in animal and epidemiological work, building in experiments that test clinical relevance, and validating findings in patient cohorts when feasible.

To support clinically meaningful and reproducible science, the opportunity highlights established resources that applicants can draw on, especially when human biospecimens or linked clinical information are important to the research plan. Examples include the PCRP-funded Prostate Cancer Biorepository Network and the North Carolina to Louisiana Prostate Cancer Project (PCaP). If a proposal depends on access to these (or similar) resources, applicants are strongly encouraged to include a letter of support demonstrating that the samples or data are available and that the team can access them in time to complete the project. The program also encourages studies that use large patient datasets with long-term health records and biospecimen repositories, particularly when paired with state-of-the-art genomic/proteomic methods, modern bioinformatics, or mathematical modeling to extract new insights.

The award includes a specific pathway for early-career researchers through a New Investigator category. This category allows investigators who are early in faculty appointments or still establishing independent research careers to compete separately from Established Investigators, provided they meet the eligibility rules described in the full announcement. A key requirement for New Investigator applicants is to include one or more collaborators with demonstrated prostate cancer expertise, evidenced by relevant funding and publications. The application must spell out how these collaborations fill gaps in the PI’s experience and strengthen the team’s ability to answer the research question, making the partnership more than a formality.

Team science is strongly supported, including multidisciplinary and multi-institutional projects. For multi-institutional efforts, the application must include a clear plan for how partners will work together in practice, covering communication routines, coordination of research activities, sharing of progress and results, and procedures for data transfer. In addition, multi-institutional applications must provide an intellectual property plan intended to prevent institutional barriers from undermining collaboration, clarifying how potential intellectual and material property issues will be handled so the project can move efficiently and cooperatively.

In terms of permissible research scope, studies involving human subjects are allowed, but clinical trials are not permitted under this funding opportunity. That said, correlative studies tied to an existing clinical trial are especially encouraged as long as they qualify as no greater than minimal risk and receive the appropriate oversight approvals, including review by the Institutional Review Board (IRB) and the USAMRDC Office of Research Protections/Human Research Protection Office (ORP/HRPO). Applicants whose main objective requires launching a clinical trial are directed instead to the separate FY20 PCRP Clinical Trial Award mechanism (W81XWH-20-PCRP-CTA).

The announcement also points applicants toward broader federal priorities around advanced and recurrent disease. It references recommendations from a Congressionally mandated Metastatic Cancer Task Force aimed at accelerating clinical and translational progress for patients with advanced-stage and recurrent cancers. Applicants are encouraged to consider those recommendations when shaping research ideas, as long as the proposed work stays within the boundaries of the Idea Development Award and aligns with FY20 PCRP priorities.

From an administrative and funding standpoint, awards are issued as assistance agreements, meaning the government is supporting a public-purpose research effort rather than purchasing a product or service for direct government use. The assistance agreement may be structured as either a grant or a cooperative agreement depending on how much involvement the DoD anticipates during performance. If substantial programmatic involvement is expected (for example, active collaboration or participation in the research), a cooperative agreement is used; if not, the award is made as a grant. The anticipated direct cost cap for the full period of performance is up to $600,000 for New Investigators and up to $750,000 for Established Investigators. The opportunity anticipated roughly 30 awards, with awards expected to be issued no later than September 30, 2021. The solicitation was posted April 7, 2020, with an original closing date of September 24, 2020, under the Department of Defense (Department of the Army, USAMRAA) and CFDA 12.420.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 07, 2020.
• Applicants must submit their applications by Sep 24, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 30 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 PCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: